Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Blood (2016) 128 (22): 621.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals